pterygium (excluding recurrent pterygium)
Conditions
Interventions
- 0.1% STN1014200 ophthalmic emulsion group: One drop twice daily (morning and evening) instilled into the eligible eye(s)
- 0.2% STN1014200 ophthalmic emulsion group: One drop twice daily (morning an
Sponsors
Inai Maya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - 18 years of age or older - Outpatient status - Diagnosed with pterygium (excluding recurrent pterygium) in at least one eye
Exclusion criteria
Exclusion criteria: - Presence of active ocular infection or conjunctivitis in either eye (excluding mild blepharitis not requiring pharmacological treatment) - History of herpetic eye disease in either eye - History of pseudopterygium, marginal corneal disease, ocular neoplasms (including non-invasive carcinoma, squamous cell carcinoma, or other tumorous conditions), or chemical/thermal ocular burns in either eye - Pregnant, breastfeeding, possibly pregnant (including positive pregnancy test), planning to become pregnant during the study period, or unwilling to use at least one of the specified contraceptive methods from informed consent through the end of the study - Determined by the investigator or sub-investigator to be unsuitable for participation in this study based on medical history, physical examination findings, clinical laboratory results, or other background information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change in the pterygium lesion length from baseline to Month 6 | — |
Contacts
Public ContactMaya Inai
Santen pharmaceutical co.,ltd
Outcome results
None listed